Toll-like receptor (TLR) signaling is essential for intestinal tumorigenesis in Apc min/+ mice, but the mechanisms by which Apc enhances tumor growth are unknown. Here we show that microflora-MyD88-ERK signaling in intestinal epithelial cells (IECs) promotes tumorigenesis by increasing the stability of the c-Myc oncoprotein. Activation of ERK (extracellular signal-related kinase) phosphorylates c-Myc, preventing its ubiquitination and subsequent proteasomal degradation. Accordingly, Apc min/+ / Myd88 −/− mice have lower phospho-ERK (p-ERK) levels and fewer and smaller IEC tumors than Apc min/+ mice. MyD88 (myeloid differentiation primary response gene 88)-independent activation of ERK by epidermal growth factor (EGF) increased p-ERK and c-Myc and restored the multiple intestinal neoplasia (Min) phenotype in Apc min/+ /Myd88 −/− mice. Administration of an ERK inhibitor suppressed intestinal tumorigenesis in EGF-treated Apc min/+ /Myd88 −/− and Apc min/+ mice and increased their survival. Our data reveal a new facet of oncogene-environment interaction, in which microflora-induced TLR activation regulates oncogene expression and related IEC tumor growth in a susceptible host.
a r t i c l e s
The gastrointestinal tract is constantly exposed to vast numbers of commensal bacteria and their inflammatory products. Essential to intestinal homeostasis are pattern recognition receptors (PRRs) such as TLRs 1 . Engagement of TLRs with their cognate ligands in the intestinal mucosa provokes the production of proinflammatory, proangiogenic and other growth factors that support IEC differentiation and proliferation 2 . In a genetically susceptible host, ongoing intestinal inflammation triggers uncontrolled growth of IECs, leading to neoplasia [3] [4] [5] . Likewise, it has been proposed that signaling through the TLR-MyD88 pathway regulates IEC tumor development in mice heterozygous for a mutant form of the tumor suppressor gene Apc (encoding adenomatous polyposis coli) 6 . However, the underlying pro-tumorigenic mechanisms of TLR signaling have not been identified. The Apc min/+ mouse is an animal model of human familial adenomatous polyposis 7 . These mice develop multiple intestinal neoplasia (Min) after they spontaneously lose the heterozygous wild-type Apc allele in certain IECs, and consequently die by the time they reach 6 months of age 8 .
The survival and growth of some tumors are dependent on the continued activation of oncogenes. This phenomenon, known as 'oncogene addiction,' explains tumor suppression that occurs as a result of the inactivation of a single gene product 9 . The oncogene c-Myc is crucial for Apc-mediated tumorigenesis 10, 11 . The genetic deletion of c-Myc in IEC of Apc min/+ mice results in the inhibition of tumor growth 11 , and reduction of c-Myc expression in IECs by as little as a factor of 2 is sufficient to inhibit tumorigenesis in these mice [12] [13] [14] . We determined that MyD88-dependent activation of ERK in IECs is essential for intestinal tumor growth in Apc min/+ mice via the stabilization of c-Myc protein. Consequently, the inhibition of p-ERK abrogates the Min phenotype in these mice.
RESULTS
MyD88 signaling is essential for polyp growth in Apc min/+ mice TLRs signal mainly through either MyD88 or Toll-like receptor adaptor molecule 1 (TRIF, also known as TICAM). To explore the potential impact of TLR signaling on IEC tumors, we therefore crossed Apc min/+ mice to Myd88 −/− or to Ticam Lps2/Lps2 (Lps2) mice 15 . The average survival was 23 weeks for Apc min/+ mice and 28 weeks for Apc min/+ /Lps2 mice. In contrast, all of the Apc min/+ /Myd88 −/− mice survived the 45-week study (Supplementary Fig. 1a ). We then determined the role of each adaptor protein in tumor (polyp) formation at in mice at 20 weeks of age. Apc min/+ /Myd88 −/− mice had fewer polyps throughout the small and large intestines than Apc min/+ or Apc min/+ /Lps2 mice ( Supplementary Fig. 1b,c) , but they showed circular raised lesions (microadenomas) in both the distal small intestine (DSI) and the colon (Supplementary Fig. 1c-f ).
MyD88 signaling regulates proliferation and apoptosis of IECs
As the polyps in the Apc min/+ /Myd88 −/− mice failed to grow ( Supplementary Fig. 1c ), we investigated whether the deletion of Myd88 affected IEC proliferation. The proliferation and migration rates of IEC along the crypt-villus axis, as measured by BrdU incorporation, were lower than in Apc min/+ mice ( Fig. 1a) . We also observed a significantly higher number of apoptotic IECs in Apc min/+ /Myd88 −/− a r t i c l e s 6 6 6 VOLUME 16 | NUMBER 6 | JUNE 2010 nature medicine ( Fig. 1b) as well as an increase in cleaved poly(ADP-ribose) polymerase (PARP), a substrate of caspase-3 (ref. 16) ( Fig. 1c) . Together, these data indicate that TLR signaling by MyD88 enhances IEC proliferation and inhibits IEC apoptosis, and suggest that these two effects synergize in enhancing IEC tumor growth in Apc min/+ mice.
MyD88 signaling in IEC controls IEC tumor growth
In the intestinal mucosa, both IEC and bone marrow-derived cells have functional TLRs that use MyD88 for signaling [17] [18] [19] . To further clarify the role of bone marrow-derived cells in IEC tumorigenesis, we generated bone marrow chimeras by reconstituting both Apc min/+ and Apc min/+ /Myd88 −/− recipients with bone marrow harvested from either WT or Myd88 −/− donors 20 . Reconstitution of Apc min/+ recipients with either Myd88 −/− or WT bone marrow did not significantly alter polyp count and growth in either the DSI or the colon. Similarly, the number of polyps did not change significantly in Apc min/+ /Myd88 −/− recipients reconstituted with WT or Myd88 −/− bone marrow ( Fig. 2a) . These results indicate that polyp growth in Apc min/+ mice does not depend on TLR-MyD88 signaling in bone marrow-derived cells, and strongly suggest that it instead depends on TLR-MyD88 activation of IECs.
To explore whether host-derived or microbial-derived TLR ligands play a role in IEC tumorigenesis, we crossed Apc min/+ mice with Il1r1 −/− or with Casp1 −/− mice, which are limited in processing interleukin (IL)-1 and IL-18 (ref. 21) . There was no significant difference in the numbers of polyps in Apc min/+ /Il1r1 −/− or Apc min/+ /Casp1 −/− as compared to Apc min/+ mice (Fig. 2b) . In addition, administration of the IL-1R antagonist anakinra did not affect the extent of IEC tumorigenesis in Apc min/+ mice ( Fig. 2c) . Collectively, these data strongly suggest that MyD88-dependent TLR activation by microbial ligands is responsible for IEC tumor growth in Apc min/+ mice.
A MyD88-dependent TLR signaling upregulates c-Myc in IECs
The decrease in IEC proliferation and the increase in IEC apoptosis in Apc min/+ /Myd88 −/− mice suggested that a MyD88-dependent oncogene or mitogen is involved in IEC tumorigenesis. Because c-Myc is essential for tumorigenesis in Apc min/+ mice 11, 12, 14 , we tested whether MyD88 regulates c-Myc expression. MyD88 deficiency resulted in a significant decrease in c-Myc protein in IECs. Whereas c-Myc was expressed throughout the crypt in both the DSI and the colon of Apc min/+ mice, its expression in Apc min/+ /Myd88 −/− mice was restricted to the base of the crypt (Fig. 3a) . Immunoblotting analysis of c-Myc in isolated IECs (in the DSI) confirmed the reduced expression of not only c-Myc, but also p-ERK, in Apc min/+ /Myd88 −/− mice ( Fig. 3b and Supplementary  Fig. 2a ). Decreased c-Myc expression in Apc min/+ /Myd88 −/− IEC was observed in both normal and tumor regions ( Supplementary  Fig. 2b) . Nevertheless, the c-Myc mRNA levels in IECs did not differ significantly between Apc min/+ and Apc min/+ /Myd88 −/− mice ( Fig. 3c) . site 3)-induced activation of β-catenin in vitro (Fig. 3d) . These data indicate that MyD88 signaling affects tumorigenesis independently of the Wnt-APC-β-catenin pathway.
Inactivation of

Post-translational modification of c-Myc by ERK
Our data suggest that MyD88-mediated signaling in IEC causes tumor growth. Because IECs express functional TLRs 18, 19 ( Supplementary  Fig. 3a) , we tested whether activation of a TLR-MyD88 pathway directly induces c-Myc expression. Indeed, TLR2 activation did enhance the abundance of c-Myc protein in the IEC line RKO (Apc wild type) ( Fig. 4a ) in a MyD88-dependent manner ( Supplementary  Fig. 3b ). Activation of TLR5 (a MyD88-dependent TLR) in RKO produced a similar result ( Supplementary Fig. 3c ). Consistent with mRNA levels observed in vivo (Fig. 3c) , the level of c-Myc mRNA was not affected by TLR2 triggering, whereas expression of IL-8 and IκBα were increased 19 (Fig. 4a) .
The increase in c-Myc protein without a concomitant increase in mRNA level after TLR stimulation suggested that c-Myc protein is subjected to post-translational modifications 22 . Indeed, inhibition of proteasomal function by MG-132 increased c-Myc protein in RKO cells without affecting the mRNA level (Fig. 4b) , indicating a steady-state degradation of c-Myc. We therefore tested whether TLR stimulation in IECs stabilizes c-Myc protein. Although the c-Myc-ubiquitin conjugates were easily detected even in the absence of a proteasome inhibitor in RKO cells, they disappeared rapidly upon TLR2 stimulation with a concomitant increase in unconjugated c-Myc protein (Fig. 4c) . Accordingly, these results suggest that the TLR-MyD88-mediated signaling pathway stabilizes c-Myc protein in IEC by inhibiting its proteasomal degradation.
The MEK-ERK pathway phosphorylates c-Myc on Ser62, which stabilizes c-Myc by preventing ubiquitination and proteasomal degradation [23] [24] [25] . We examined whether Myd88-mediated activation of ERK is responsible for the stabilization of c-Myc. TLR2 activation did induce the phosphorylation of ERK as well as that of c-Myc on Ser62 (Fig. 4a) . In addition, blocking ERK activation with pharmacological inhibitors rapidly reduced c-Myc abundance (Fig. 4d) . Caco-2, another IEC line, expresses a truncated APC protein similar to that observed in Apc min/+ mice 26 . We therefore tested whether MyD88dependent ERK activation can stabilize c-Myc in these Apc mutant cells. TLR2 stimulation increased c-Myc protein abundance with a concomitant ERK activation and decrease in the polyubiquitinated c-Myc (Supplementary Fig. 4a,b) . Similarly, stimulation of either TLR2 or the epidermal growth factor receptor (EGFR) in a nontransformed IEC line derived from the small intestine (RIE-1) also activated ERK and c-Myc (Supplementary Fig. 4c) a r t i c l e s in non-transformed IECs (Supplementary Fig. 4c ), we treated Apc min/+ /Myd88 −/− mice either with EGF alone or with EGF plus a MEK1/2 inhibitor (PD0325901, PD). The latter is a specific and effective pharmacological inhibitor of ERK 27 and is in phase 2 clinical trials in cancer. The administration of EGF significantly increased the number of polyps in the DSI (see Supplementary Fig. 1b ), but this induction was abrogated by PD treatment (Fig. 5a) . Serum hemoglobin and body weights drop significantly in Apc min/+ mice over time as a result of increasingly large and abundant exophytic polypoid intestinal tumors that minimize food absorption and cause subsequent intestinal obstruction and bleeding 28 . The inhibition of tumor growth in PD-treated Apc min/+ /Myd88 −/− mice coincided with increased serum hemoglobin concentrations ( Fig. 5b) and increased body weight (Fig. 5c) , indicative of better health. As expected, EGF administration enhanced the abundance of c-Myc and p-ERK in IECs, which was reversed by PD treatment (Fig. 5d) . Hence, the inhibition of IEC tumors in PD-treated mice further validated the regulatory role of ERK on tumorigenesis in Apc min/+ /Myd88 −/− mice (Fig. 3b) and may suggest that the TLR-MyD88 pathway is a major contributor to ERK activation in Apc min/+ mice in steady-state conditions. These results suggest a pivotal role for ERK activation of the Min phenotype. We therefore tested its tumorigenic role in 10-week-old Apc min/+ mice. PD treatment of these mice for 14 weeks resulted in complete inhibition of polyp growth (Fig. 6a) with an associated increase in serum hemoglobin concentrations (Fig. 6b) and body weight (Fig. 6c) . PD treatment also inhibited both c-Myc and p-ERK in IECs of these mice (Fig. 6d,e) . Furthermore, in another study, PD treatment of 10-week-old Apc min/+ mice resulted in 100% survival, whereas treatment with vehicle resulted in 100% mortality during the following 17-week treatment period (Fig. 6f) . To detect the longterm effects of PD treatment, we continued to deliver it or vehicle to PD-treated Apc min/+ mice for an additional 15 weeks. Continuous PD treatment inhibited tumorigenesis, whereas its discontinuation resulted in high tumor counts ( Fig. 6g) . Collectively, these results indicate that the regulation of the ERK pathway in Apc min/+ mice controls intestinal tumorigenesis and the subsequent manifestation of the Min phenotype, most likely by post-translational modifications of c-Myc protein.
DISCUSSION
Overt inflammation can promote neoplasia [29] [30] [31] [32] . TLR activation of innate immune cells (for example, macrophages) in the intestinal mucosa triggers the production of various pro-inflammatory mediators 3, 5 . This mechanism was proposed to enhance tumorigenesis in the Apc min/+ mice 6 . However, our study indicates that in non-hematopoietic cells, such as IECs, MyD88 is required for intestinal tumor growth in the Apc min/+ mouse. Furthermore, we found that TLR ligands, presumably from intestinal flora ( Fig. 4) and not from the host (Fig. 2) , mediate IEC tumor growth under steady-state conditions. In this setting, MyD88-mediated signaling induces ERK activation that stabilizes and thus increases the abundance of the Myc protein, the product of the oncogene Myc (c-Myc), in IECs 23 . This sequence of events enhances IEC proliferation and reduces IEC apoptosis and therefore promotes IEC tumor growth in Apc min/+ mice. The oncogene Myc is a Wnt target gene 33, 34 . Although β-catenin-TCF signaling induces Myc transcriptionally, the gene's expression levels are heavily regulated by ubiquitin-mediated proteasomal degradation 35, 36 , which can be antagonized by p-ERK phosphorylation of c-Myc [23] [24] [25] . Our findings indicate that MyD88-dependent activation of ERK is necessary to stabilize c-Myc levels (Fig. 4) ; that the activation of ERK by the MyD88-independent ligand EGF 37 increases expression of c-Myc and restores the Min phenotype in Apc min/+/ Myd88 −/− mice (Fig. 5) ; and that treatment with a specific ERK inhibitor suppresses tumor development in both Apc min/+ and EGF-treated Apc min/+ /Myd88 −/− mice ( Figs. 5 and 6) . Collectively, these data indicate that (i) loss of heterozygosity of Apc is insufficient to drive the Min phenotype in the Apc min/+ mouse, (ii) synergy between c-Myc transcription and post-translational modifications is required for tumor growth in this model, (iii) activation of ERK is necessary for IEC tumorigenesis in the Apc min/+ mouse and (iv) ERK functions as a major regulator of c-Myc expression in the intestinal epithelium ( Fig. 6h) .
Oncogene addiction is a mechanism that explains tumor suppression due to the inactivation of a single gene product. This phenomenon occurs when tumors require sustained activation of a single oncogene for their growth and survival, despite other oncogenic events 9 . Our data reveal that IEC tumor growth in the Apc min/+ mice is due to p-ERK addiction. ERK addiction was also recently shown to drive the survival of certain intestinal epithelial cell lines in vitro 38 , although by a different pathway. Activation of ERK in this setting is most likely induced by a TLR-MyD88-dependent pathway (for example, microflora) ( Fig. 3) and by a TLR-MyD88-independent pathway (for example, growth factors) ( Fig. 5) . Consequently, the inhibition of ERK prevents tumorigenesis in Apc min/+ mice, most likely through the generation of an unstable c-Myc protein ( Figs. 5  and 6 ), leading to low c-Myc abundance in IECs (Fig. 3) . Although regulation of the ERK-c-Myc pathway inhibits the Min phenotype under steady-state conditions, we cannot rule out other anti-apoptotic effects caused by p-ERK that may influence the Min phenotype 38 . The disparity in tumor numbers between Apc min/+ and Apc min/+/ Myd88 −/− mice (Supplementary Fig. 1) , as well as the biochemical evidence presented above in vitro ( Fig. 4) and in vivo ( Figs. 5 and 6) , strongly support the inductive role of microflora-derived MyD88 signaling on IEC tumorigenesis in Apc min/+ mice. These observations suggest a new facet of oncogene-environment interactions, which might explain why a germline mutation in Apc results primarily in tumors originating in the intestinal epithelium ( Fig. 6h) and not in other organs. Because p-ERK is important in the induction of the Min phenotype (Figs. 5  and 6) , we propose that interventions aimed at inhibiting ERK activation in IECs (Fig. 6) may help suppress the induction of IEC neoplasia in humans with variant APC genes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website. a r t i c l e s
